Survodutide (survodutide (BI 456906))
Dual agonist showing strong weight loss + liver benefits in NASH trials.
Survodutide (BI 456906) is a dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials showed ~19% weight loss over 46 weeks; Phase 3 trials in obesity and MASH/NASH are ongoing.
Overview
Survodutide is currently in Phase 3 development for obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis). Unlike tirzepatide (GLP-1 + GIP), survodutide combines GLP-1 with glucagon agonism — different from retatrutide because no GIP component.
How Survodutide Works
GLP-1 reduces appetite and slows gastric emptying. Glucagon receptor agonism increases energy expenditure and may directly target liver fat — making survodutide particularly promising for MASH/NASH.
Dosing & Schedule
Phase 2 weekly doses 0.6-4.8 mg. Phase 3 doses still being finalized.
Effectiveness — Trial Data
Phase 2: 19% weight loss at top dose. MASH trial showed strong reduction in liver fat.
Side Effects
Similar GI profile to other GLP-1s. Glucagon agonism could theoretically raise blood sugar, monitored in trials.
Cost — How Much Survodutide Costs in 2026
Not yet on market. Expected approval 2026-2027.
Who Is Survodutide For?
Investigational. Once approved, likely indicated for obesity, type 2 diabetes, and MASH/NASH.
Survodutide Alternatives
Available now: tirzepatide, semaglutide.